CUE
Cue Biopharma, Inc. NASDAQ Listed Jan 2, 2018$35.74
Mkt Cap $93.9M
52w Low $4.98
84.4% of range
52w High $41.42
50d MA $12.67
200d MA $16.74
P/E (TTM)
-3.6x
EV/EBITDA
-0.3x
P/B
3.6x
Debt/Equity
0.2x
ROE
-100.6%
P/FCF
-1.3x
RSI (14)
—
ATR (14)
—
Beta
1.58
50d MA
$12.67
200d MA
$16.74
Avg Volume
333.2K
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
21 Erie Street · Boston, MA 02139 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | AMC | -2.70 | 0.30 | +111.1% | 9.35 | -4.7% | -12.8% | -2.7% | +0.0% | +0.5% | +0.3% | — |
| Nov 12, 2025 | AMC | -0.10 | -0.07 | +30.0% | 20.03 | -0.4% | -7.2% | +1.7% | -8.9% | +1.0% | +0.1% | — |
| Aug 12, 2025 | AMC | -0.13 | -0.09 | +30.8% | 23.70 | +2.5% | +2.6% | -2.5% | +4.6% | -0.9% | -0.3% | — |
| May 12, 2025 | AMC | -0.14 | -0.17 | -21.4% | 22.53 | -2.8% | +2.3% | -3.0% | -2.9% | +0.2% | -2.4% | — |
| Mar 31, 2025 | AMC | -0.16 | -0.13 | +18.8% | 27.33 | -0.1% | -17.7% | +5.3% | -3.7% | -11.3% | -7.3% | — |
| Nov 14, 2024 | AMC | -0.20 | -0.17 | +15.0% | 45.00 | +0.0% | -16.7% | -12.0% | -1.8% | +0.9% | -5.5% | — |
| Aug 19, 2024 | AMC | -0.29 | -0.20 | +31.0% | 22.80 | +1.3% | +13.7% | +4.7% | -9.9% | -5.6% | -5.0% | — |
| May 9, 2024 | AMC | -0.30 | -0.25 | +16.7% | 57.60 | +0.5% | -9.4% | -5.2% | -6.1% | +5.8% | +6.1% | — |
| Apr 8, 2024 | AMC | -0.30 | -0.28 | +6.7% | 61.20 | -4.9% | -6.9% | -6.3% | -1.1% | -0.6% | -8.6% | — |
| Nov 9, 2023 | AMC | -0.30 | -0.24 | +20.0% | 62.25 | -0.7% | +11.3% | +3.5% | +2.9% | -3.3% | +0.0% | — |
| Aug 9, 2023 | AMC | -0.30 | -0.29 | +3.3% | 108.60 | +3.0% | -13.3% | -3.5% | +1.3% | -8.5% | +7.1% | — |
| May 9, 2023 | AMC | -0.33 | -0.29 | +12.1% | 145.50 | +2.5% | -2.5% | -0.8% | -8.3% | +3.5% | -4.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 2 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $22.50 | $22.02 | -2.1% | +5.3% | -3.7% | -11.3% | -7.3% | -1.3% |
| Aug 20 | Stifel | Maintains | Buy → Buy | — | $22.80 | $23.10 | +1.3% | +13.7% | +4.7% | -9.9% | -5.6% | -5.0% |
| Jul 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $21.10 | $21.03 | -0.3% | -4.7% | -3.5% | +18.3% | +9.2% | -7.2% |
| Jul 26 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $21.10 | $21.03 | -0.3% | -4.7% | -3.5% | +18.3% | +9.2% | -7.2% |
| Apr 9 | Stifel | Maintains | Buy → Buy | — | $61.20 | $58.20 | -4.9% | -6.9% | -6.3% | -1.1% | -0.6% | -8.6% |
| Apr 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $61.20 | $58.20 | -4.9% | -6.9% | -6.3% | -1.1% | -0.6% | -8.6% |
| Apr 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $54.60 | $54.00 | -1.1% | -2.7% | +0.6% | +3.9% | +10.3% | -6.9% |
| Nov 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $73.50 | $76.80 | +4.5% | +4.1% | +0.0% | -8.2% | -11.3% | +11.3% |
| Jun 15 | Stifel | Maintains | Buy → Buy | — | $113.40 | $114.60 | +1.1% | +2.4% | +3.9% | +0.5% | -5.2% | +1.8% |
| May 15 | JMP Securities | Maintains | Outperform → Outperform | — | $129.00 | $131.70 | +2.1% | +3.5% | -4.5% | -4.7% | -1.5% | +5.3% |
| Mar 22 | Oppenheimer | Maintains | Outperform → Outperform | — | $101.40 | $101.40 | +0.0% | -2.1% | -0.3% | +0.6% | -6.0% | +10.9% |
| Mar 22 | Stifel | Maintains | Buy → Buy | — | $101.40 | $101.40 | +0.0% | -2.1% | -0.3% | +0.6% | -6.0% | +10.9% |
| Nov 21 | Piper Sandler | Maintains | Overweight → Overweight | — | $96.60 | $102.30 | +5.9% | -2.8% | +1.6% | +10.7% | +0.0% | +0.3% |
| Aug 24 | Oppenheimer | Maintains | Outperform → Outperform | — | $96.60 | $95.70 | -0.9% | -6.5% | -1.7% | -5.1% | +1.1% | -1.4% |
| Mar 21 | Oppenheimer | Maintains | Outperform → Outperform | — | $167.40 | $168.90 | +0.9% | +0.5% | -2.5% | -4.6% | -0.8% | -3.3% |
| Mar 18 | Craig-Hallum | Maintains | Buy → Buy | — | $165.60 | $162.90 | -1.6% | +1.1% | +0.5% | -2.5% | -4.6% | -0.8% |
| Nov 24 | Berenberg | Maintains | Buy → Buy | — | $360.30 | $376.88 | +4.6% | +3.1% | +2.6% | +8.2% | +1.8% | -1.2% |
| May 20 | Oppenheimer | Maintains | Outperform → Outperform | — | $814.20 | $863.70 | +6.1% | +6.0% | +6.2% | -1.4% | -3.8% | -6.2% |
| May 20 | Stifel | Maintains | Buy → Buy | — | $814.20 | $863.70 | +6.1% | +6.0% | +6.2% | -1.4% | -3.8% | -6.2% |
| Apr 21 | Stifel | Maintains | Buy → Buy | — | $645.00 | $664.20 | +3.0% | +0.0% | +6.7% | +6.9% | -1.1% | +1.7% |
| Apr 9 | Stifel | Maintains | Buy → Buy | — | $498.00 | $532.80 | +7.0% | +8.3% | +4.1% | +5.4% | -0.9% | -4.7% |
| Mar 6 | JMP Securities | Maintains | Outperform → Outperform | — | $668.10 | $663.30 | -0.7% | -7.9% | -11.3% | -4.9% | -9.2% | -20.4% |
| Feb 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $558.00 | $582.00 | +4.3% | +1.5% | +0.3% | -5.7% | -2.0% | +3.5% |
| Jan 28 | BTIG | Maintains | Buy → Buy | — | $465.30 | $479.70 | +3.1% | +4.2% | +1.5% | -6.9% | -0.7% | +3.6% |
| Jan 22 | JMP Securities | Maintains | Market Outperform → Outperform | — | $450.00 | $463.20 | +2.9% | +2.3% | -1.0% | +0.1% | +2.0% | +4.2% |
| Jul 26 | Baird | Maintains | Outperform → Outperform | — | $205.20 | $210.60 | +2.6% | +8.2% | -0.5% | +5.6% | +6.9% | -1.4% |
No insider trades available.
8-K
Cue Biopharma, Inc. -- 8-K Filing
Cue Biopharma secured a partnership deal potentially worth up to $216.5 million in upfront and milestone payments, plus royalties on future net sales of licensed products.
May 1
8-K · 5.03
! Medium
Cue Biopharma, Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Cue Biopharma amended its articles or bylaws, a governance change that may affect shareholder rights or operational procedures but typically has minimal direct impact on the company's near-term business prospects.
Apr 22
8-K
Unknown — 8-K Filing
The sudden CEO resignation at Cue Health signals potential leadership instability and uncertainty about company direction, which typically pressures stock prices until a qualified successor is named and market confidence is restored.
Apr 13
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
The 8-K indicates Cue Health disclosed material risks affecting future results, warranting investor scrutiny of revised business outlook and competitive positioning.
Apr 7
8-K
Unknown — 8-K Filing
CUE's appointment of an experienced pharmaceutical executive with Janssen background strengthens leadership for business development and international expansion, potentially signaling confidence in growth strategy execution.
Mar 27
8-K
Unknown — 8-K Filing
Curevac's achievement of 2025 development milestones strengthens its pipeline credibility, potentially validating its T-cell modulation approach and supporting future funding/partnership prospects critical for this cash-burning clinical-stage biotech.
Mar 16
8-K · 8.01
!! High
Cue Biopharma, Inc. -- 8-K 8.01: Material Event / Announcement
Cue Biopharma announced the deadline for stockholders to submit proposals for inclusion in the 2026 Annual Meeting proxy statement, establishing governance participation opportunities for shareholders.
Feb 18
8-K · 5.02
!!! Very High
Cue Biopharma, Inc. -- 8-K 5.02: Executive Change
Cue Biopharma appoints Lucinda Warren as Chief Financial Officer effective February 9, 2026, signaling potential strategic financial changes ahead.
Feb 12
Data updated apr 25, 2026 3:55am
· Source: massive.com